Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Stomach Neoplasms 3Neoplasm Metastasis 3Recurrence 2Nasopharyngeal Carcinoma 2Melanoma 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Prostatic Neoplasms 1Perioperative Treatment in Subjects With Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Cancer 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Lymphoma 1Lung Neoplasms 1Locally Advanced Colorectal Cancer 1Hodgkin Disease 1HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma 1Gastric Adenocarcinoma 1Colorectal Cancer Metastatic 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Advanced or Metastatic Non-squamous Non-small-cell Lung Cancer 1Advanced Solid Tumor 1Advanced Malignant Tumors 1Advanced Gastric Cancer 1

Interventions

Cyclophosphamide 193fludarabine phosphate 121Peripheral Blood Stem Cell Transplantation 106Etoposide 106Mycophenolic Acid 94Filgrastim 91Doxorubicin 85Whole-Body Irradiation 83Tacrolimus 80Melphalan 78Brentuximab Vedotin 77Busulfan 74Radiotherapy 73fludarabine 67Cyclosporine 67Vinblastine 65Rituximab 60Dacarbazine 56Granulocyte Colony-Stimulating Factor 53Gemcitabine 52Antilymphocyte Serum 51Bleomycin 50Nivolumab 47Methotrexate 47Vincristine 46Prednisone 45Cytarabine 43pembrolizumab 36Carmustine 36Bendamustine Hydrochloride 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Hodgkin Disease × SHR-1701 × Clear all
NCT05896046 2023-06-15

SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma

Chinese PLA General Hospital

Phase 1/2 Unknown
100 enrolled
Lymphoid

Hodgkin Disease, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡